At Orio Therapeutics, our mission is to save lives by making the regenerative medicine dream accessible and a wide-spread reality. We are dedicated to developing novel regenerative drugs with increased efficacy and reduced side-effects, using cutting-edge targeted drug-delivery technologies to create novel therapeutic proteins. Notably, we strive to demonstrate that efficient drug delivery technologies are not confined to the development of complex devices and drug carriers but can be achieved based on clever molecular designs. We aim to initially validate our program pipeline through the development of a therapeutic molecule for myocardial infarction that has the potential to change the lives of patients following myocardial infarction by enabling faster recovery time and improved heart function.
Company Details
- Employees
- 2
- Founded
- -
- Address
- Route De L'ile-Au-Bois 3, Monthey,valais 1870,switzerland
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://oriotx.com
- HQ
- Monthey, Valais
Orio Therapeutics Questions
Orio Therapeutics's website is http://oriotx.com
Orio Therapeutics's LinkedIn profile is https://ch.linkedin.com/company/oriotx
Orio Therapeutics has
2 employees.
View email and phone details for 2
employees at Orio Therapeutics.
Orio Therapeutics's industry is
Biotechnology Research
Orio Therapeutics's top competitors are
Curio Biotech Ltd,
Excellgene Sa,
Immunskills Sa,
Ninsun Biotech,
Ceidos,
Nagi Bioscience,
Eosgene Therapeutics,
Novochizol Sa,
Rem Analytics,
Bioark.
Orio Therapeutics's categories are Biotechnology Research
Orio Therapeutics's founding year is 2023
